prevention of neonatal jaundice and increasing the volum of breast milk. Neonatal jaundice, unspecified
Conditions
Interventions
Intervention 1: The intervention group will receive Metoclopramide tablet, 10 mg three times per day for five days. Intervention 2: The control group will receive 10 mg placebo tablet three times per
Treatment - Drugs
Placebo
The intervention group will receive Metoclopramide tablet, 10 mg three times per day for five days
The control group will receive 10 mg placebo tablet three times per day for five days.
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 49 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Healthy full-term pregnancy; Mothers with singleton pregnancy; Being Lactating, and having tendency and motivation to breast-feeding; Living in Tabriz; Willingness to continue in the study; -Having at least literacy of reading and writing. Exclusion criteria: Newborns with birth defects; Newborns that need to neonatal intensive cares; Neonatal jaundice in first day after birth; Neonatal metabolic disease; Taking of hormonal drugs by mothers such as estrogen; Taking of medications that affect the serum prolactin like halopridol, reserpine, mytel- dopa, opiates and cimetidine; Maternal depression; History of previous depression; Inverted nipple; Having absolute or relative contraindication for breast-feeding in the mother including diseases such as untreated TB, infection with HIV, CMV, herpes simplex virus and hepatitis and taking of radioactive drugs and illegal drugs during the breastfeeding period, such as methotrexate, lithium, cyclophosphamide, hydroxyurea, phencyclidine, phenidone, opiate substances and metronidazole; History of chronic disease in the mother
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Newborn’s bilirubin. Timepoint: Before intervention and sixth day after the intervention. Method of measurement: TCB.;Mother’s prolactin serum level. Timepoint: Next day after starting of the intervention and sixth day. Method of measurement: Prolactin ELISA Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume of breast milk. Timepoint: Two hours after the last breastfeeding in the first and sixth day of intervention. Method of measurement: Syringe.;Satisfaction from breastfeeding status. Timepoint: After the end of intervention. Method of measurement: Satisfaction checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShirin Osouli Tabrizi
Tabriz University of Medical Sciences
Outcome results
None listed